Structure Therapeutics price target raised to $120 from $87 at Citizens

Citizens raised the firm’s price target on Structure Therapeutics (GPCR) to $120 from $87 and keeps an Outperform rating on the shares. The Phase 2b data for aleniglipron fundamentally derisk the small molecule GLP agonist, and the firm is not losing the forest through the trees, the analyst tells investors in a research note. There could be ongoing debate on aleniglipron’s tolerability, but there is solid evidence to support an improved Phase 3 profile, the firm adds.